Drugs with the highest drug expenditure in the Republic of Serbia

Introduction: The policy concerning drugs represents a concentrated effort to achieve better health outcomes for all, with a particular focus on people's access to and rational use of medications. On the basis of pharmacoeconomic analyses, it is possible to modify established prescribing habits...

Full description

Bibliographic Details
Main Authors: Milijašević Boris Ž., Milak Anđela D., Ubavić Milan B., Krtinić Dane A., Nedin-Ranković Gorana G., Jovanović Hristina M., Trajković Hristina S., Milijašević Dragana S., Popović Radmila N., Todorović Nemanja B., Lalić-Popović Mladena N., Vukosav Nikola B., Baljak Branko M., Tošić Milan S., Matijević Radmila N.
Format: Article
Language:English
Published: Srpsko lekarsko drustvo 2023-01-01
Series:Hospital Pharmacology
Subjects:
Online Access:https://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2023/2334-94922302301M.pdf
_version_ 1797662786274197504
author Milijašević Boris Ž.
Milak Anđela D.
Ubavić Milan B.
Krtinić Dane A.
Nedin-Ranković Gorana G.
Jovanović Hristina M.
Trajković Hristina S.
Milijašević Dragana S.
Popović Radmila N.
Todorović Nemanja B.
Lalić-Popović Mladena N.
Vukosav Nikola B.
Baljak Branko M.
Tošić Milan S.
Matijević Radmila N.
author_facet Milijašević Boris Ž.
Milak Anđela D.
Ubavić Milan B.
Krtinić Dane A.
Nedin-Ranković Gorana G.
Jovanović Hristina M.
Trajković Hristina S.
Milijašević Dragana S.
Popović Radmila N.
Todorović Nemanja B.
Lalić-Popović Mladena N.
Vukosav Nikola B.
Baljak Branko M.
Tošić Milan S.
Matijević Radmila N.
author_sort Milijašević Boris Ž.
collection DOAJ
description Introduction: The policy concerning drugs represents a concentrated effort to achieve better health outcomes for all, with a particular focus on people's access to and rational use of medications. On the basis of pharmacoeconomic analyses, it is possible to modify established prescribing habits, it is possible to influence the creation of guidelines, development strategy and long-term health care planning. Aim: The aim of the work was to determine drugs with the highest expenditure in the Republic of Serbia, and to compare the results obtained in three consecutive years 2016, 2017 and 2018. Also, to analyze which are the most expensive medications listed in the National Register of Medications and what is the trend of changing them. Material and methods: The drug expenditure was monitored using the ATC/DDD methodology. It implies the classification of medications according to the internationally accepted ATC classification of drugs, while DDD, i.e. defined daily dose, is used as a statistical unit for consumption monitoring. The number of DDD/1,000 inhabitants per day provides an insight into how many inhabitants (out of 1,000 of them) used the observed medication and were exposed to its effects during one day. Results: The trend of expenditure of these medications was growing exponentially from 2016 to 2018. The most expensive medications per box are from group J - anti-infective drugs for systemic use and L - antineoplastics and immunomodulators, but their expenditure in the Republic of Serbia is very low. The drugs with the highest price per 1 DDD are: enzymes imiglucerase, laronidase and the biological medication basiliximab in all three years, but considering the indications and rare prescribing, the total cost for these drugs is not high. The largest funds in the Republic of Serbia for the mentioned period were spent on drugs such as: acetylsalicylic acid, paracetamol in combinations, trastuzumab, pantoprazole, amlodipine and rosuvastatin. Comparing the spending on L group of drugs in 2017 compared to 2016, there was a significant increase. Conclusion: The medications with the highest expenditure in the Republic of Serbia are used very little compared to countries with good pharmacotherapy practice. The most expensive drugs are those that are used for special and rare indications, and large amounts of money are not allocated for them as for some cheaper, but more frequently prescribed drugs.
first_indexed 2024-03-11T19:05:12Z
format Article
id doaj.art-44fffb3e67424d92a02414813df5b99d
institution Directory Open Access Journal
issn 2334-9492
language English
last_indexed 2024-03-11T19:05:12Z
publishDate 2023-01-01
publisher Srpsko lekarsko drustvo
record_format Article
series Hospital Pharmacology
spelling doaj.art-44fffb3e67424d92a02414813df5b99d2023-10-10T08:36:10ZengSrpsko lekarsko drustvoHospital Pharmacology2334-94922023-01-011021301131310.5937/hpimj2302301M2334-94922302301MDrugs with the highest drug expenditure in the Republic of SerbiaMilijašević Boris Ž.0https://orcid.org/0000-0003-4555-8801Milak Anđela D.1Ubavić Milan B.2Krtinić Dane A.3https://orcid.org/0000-0002-9781-8727Nedin-Ranković Gorana G.4https://orcid.org/0000-0002-3954-2638Jovanović Hristina M.5Trajković Hristina S.6Milijašević Dragana S.7Popović Radmila N.8Todorović Nemanja B.9https://orcid.org/0000-0002-1519-5643Lalić-Popović Mladena N.10https://orcid.org/0000-0001-8354-3868Vukosav Nikola B.11Baljak Branko M.12Tošić Milan S.13Matijević Radmila N.14https://orcid.org/0000-0002-4993-9399University of Novi Sad, Faculty of Medicine, Department of Pharmacology, Toxicology and Clinical Pharmacology, Novi Sad, SerbiaUniversity of Novi Sad, Faculty of Medicine, Department of Pharmacology, Toxicology and Clinical Pharmacology, Novi Sad, SerbiaMedlab, Institute for Laboratory Diagnostics, Novi Sad, SerbiaUniversity of Niš, Faculty of Medicine, Department for Pharmacology with Toxicology, Niš, SerbiaUniversity of Niš, Faculty of Medicine, Department for Pharmacology with Toxicology, Niš, SerbiaUniversity of Niš, Faculty of Medicine, Department for Pharmacology with Toxicology, Niš, SerbiaUniversity of Niš, Faculty of Medicine, Department for Pharmacology with Toxicology, Niš, SerbiaUniversity of Novi Sad, Faculty of Medicine Novi Sad, Novi Sad, SerbiaUniversity of Novi Sad, Faculty of Medicine Novi Sad, Novi Sad, SerbiaUniversity of Novi Sad, Faculty of Medicine, Department of Pharmacy, Novi Sad, SerbiaUniversity of Novi Sad, Faculty of Medicine, Department of Pharmacy, Novi Sad, SerbiaUniversity of Novi Sad, Faculty of Medicine Novi Sad, Novi Sad, SerbiaUniversity of Novi Sad, Faculty of Medicine Novi Sad, Novi Sad, SerbiaUniversity of Novi Sad, Faculty of Medicine Novi Sad, Novi Sad, SerbiaUniversity of Novi Sad, Faculty of Medicine Novi Sad, Novi Sad, SerbiaIntroduction: The policy concerning drugs represents a concentrated effort to achieve better health outcomes for all, with a particular focus on people's access to and rational use of medications. On the basis of pharmacoeconomic analyses, it is possible to modify established prescribing habits, it is possible to influence the creation of guidelines, development strategy and long-term health care planning. Aim: The aim of the work was to determine drugs with the highest expenditure in the Republic of Serbia, and to compare the results obtained in three consecutive years 2016, 2017 and 2018. Also, to analyze which are the most expensive medications listed in the National Register of Medications and what is the trend of changing them. Material and methods: The drug expenditure was monitored using the ATC/DDD methodology. It implies the classification of medications according to the internationally accepted ATC classification of drugs, while DDD, i.e. defined daily dose, is used as a statistical unit for consumption monitoring. The number of DDD/1,000 inhabitants per day provides an insight into how many inhabitants (out of 1,000 of them) used the observed medication and were exposed to its effects during one day. Results: The trend of expenditure of these medications was growing exponentially from 2016 to 2018. The most expensive medications per box are from group J - anti-infective drugs for systemic use and L - antineoplastics and immunomodulators, but their expenditure in the Republic of Serbia is very low. The drugs with the highest price per 1 DDD are: enzymes imiglucerase, laronidase and the biological medication basiliximab in all three years, but considering the indications and rare prescribing, the total cost for these drugs is not high. The largest funds in the Republic of Serbia for the mentioned period were spent on drugs such as: acetylsalicylic acid, paracetamol in combinations, trastuzumab, pantoprazole, amlodipine and rosuvastatin. Comparing the spending on L group of drugs in 2017 compared to 2016, there was a significant increase. Conclusion: The medications with the highest expenditure in the Republic of Serbia are used very little compared to countries with good pharmacotherapy practice. The most expensive drugs are those that are used for special and rare indications, and large amounts of money are not allocated for them as for some cheaper, but more frequently prescribed drugs.https://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2023/2334-94922302301M.pdfdrugs expenditurethe most expensive drugsdrugs price
spellingShingle Milijašević Boris Ž.
Milak Anđela D.
Ubavić Milan B.
Krtinić Dane A.
Nedin-Ranković Gorana G.
Jovanović Hristina M.
Trajković Hristina S.
Milijašević Dragana S.
Popović Radmila N.
Todorović Nemanja B.
Lalić-Popović Mladena N.
Vukosav Nikola B.
Baljak Branko M.
Tošić Milan S.
Matijević Radmila N.
Drugs with the highest drug expenditure in the Republic of Serbia
Hospital Pharmacology
drugs expenditure
the most expensive drugs
drugs price
title Drugs with the highest drug expenditure in the Republic of Serbia
title_full Drugs with the highest drug expenditure in the Republic of Serbia
title_fullStr Drugs with the highest drug expenditure in the Republic of Serbia
title_full_unstemmed Drugs with the highest drug expenditure in the Republic of Serbia
title_short Drugs with the highest drug expenditure in the Republic of Serbia
title_sort drugs with the highest drug expenditure in the republic of serbia
topic drugs expenditure
the most expensive drugs
drugs price
url https://scindeks-clanci.ceon.rs/data/pdf/2334-9492/2023/2334-94922302301M.pdf
work_keys_str_mv AT milijasevicborisz drugswiththehighestdrugexpenditureintherepublicofserbia
AT milakanđelad drugswiththehighestdrugexpenditureintherepublicofserbia
AT ubavicmilanb drugswiththehighestdrugexpenditureintherepublicofserbia
AT krtinicdanea drugswiththehighestdrugexpenditureintherepublicofserbia
AT nedinrankovicgoranag drugswiththehighestdrugexpenditureintherepublicofserbia
AT jovanovichristinam drugswiththehighestdrugexpenditureintherepublicofserbia
AT trajkovichristinas drugswiththehighestdrugexpenditureintherepublicofserbia
AT milijasevicdraganas drugswiththehighestdrugexpenditureintherepublicofserbia
AT popovicradmilan drugswiththehighestdrugexpenditureintherepublicofserbia
AT todorovicnemanjab drugswiththehighestdrugexpenditureintherepublicofserbia
AT lalicpopovicmladenan drugswiththehighestdrugexpenditureintherepublicofserbia
AT vukosavnikolab drugswiththehighestdrugexpenditureintherepublicofserbia
AT baljakbrankom drugswiththehighestdrugexpenditureintherepublicofserbia
AT tosicmilans drugswiththehighestdrugexpenditureintherepublicofserbia
AT matijevicradmilan drugswiththehighestdrugexpenditureintherepublicofserbia